close Video Marine veteran pushes for use of psychedelic-assisted therapies for PTSD Juliana Mercer, director of public policy for the nonprofit organization Healing Breakthrough in San Diego, discusses how treatment involving MDMA can improve veterans' mental health challenges. This story discusses suicide. If you or someone you know is having thoughts of suicide, please contact the Suicide & Crisis Lifeline at 988 or 1-800-273-TALK (8255).
A U.S. Food and Drug Administration (FDA) panel rejected MDMA-based treatments for post-traumatic stress disorder (PTSD) that are often used in veteran care.
On June 4, the advisory committee voted 10-1 against the overall benefits of MDMA when used to treat PTSD, according to the Associated Press. MARINE VET TOUTS BENEFITS OF PSYCHEDELIC-ASSISTED PTSD DRUGS AS FDA CONSIDERS MDMA APPROVAL During the nine-hour-long hearing — which was held in Silver Spring, Maryland — the panel addressed some concerns about study flaws, unclear data and potentially damaging side effects, leading to another 9-2 vote against drug efficacy. The drug application for psychedelic-assisted therapies was filed by Lykos Therapeutics in California earlier this year.
"When I heard the verdict, all I could think about was the hopes of those veterans being dashed ...
and not having a solution for them," one advocate said. (iStock) The company expressed its disappointment in the FDA’s decision in a statement on June 4. "We are disappointed in today's vote, given t.